跳至主要内容
临床试验/CTRI/2019/01/017096
CTRI/2019/01/017096已完成2/3 期

An open labeled, randomized, comparative study to evaluate the Effectiveness of GanjhuVirTM a herbal antiviral in Cases of Dengue Fever with Thrombocytopenia

Radhika Ayurveda Research and Development1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年1月30日最近更新:

试验速览

阶段
2/3 期
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Change in mean platelet count

研究概览

简要总结

It is an open labeled, randomized,comparative study to evaluate the Effectivenessof GanjhuVirTM a herbal antiviral in Cases of Dengue Fever withThrombocytopenia. he study will be conducted asper computer generated randomization list, subject will either be randomized todrug group or control  group in 1:1ratio. Subjects will be advised to take given medication in a dose of 5 mlthrice daily orally after meals with water for 05 days. The primary objectivesof the study will be to assess change in mean platelet count. The secondaryobjectives will be to assess for overall improvement, percentage ofparticipants with adverse events, vitals, tolerability of study drugs andchanges in myalgia recovery from baseline to 5 days

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1.Male or Female Subject aged between 18 and 60 years 2.Diagnosis confirmed as DF Grade
  • 3.Platelet count is below 100,000 and above 30,000 per µL 4.ALT/SGPT level less than 165 U/L 5.Subject willingly giving written informed consent.

排除标准

  • 1.Patient diagnosed with DHF Grade 3 or 4 2.Platelet levels are less than 30,000 per µL 3.Patient is either pregnant or lactating 4.Has received blood products or blood transfusion during the current hospital stay Or during last one month 5.Is the patient diagnosed with ITP, Leukaemia or Hemophilia 6.Serum Creatinine is more than 1.4 mg/dl (if female) or 1.5mg/dl (if male) 7.Patient has participated in another trial within past one month 8.Patient with positive HIV infection 9.The investigator can exclude patient at his/her discretion depending upon the condition of the patient.

结局指标

主要结局

Change in mean platelet count

时间窗: Screening visit, Visit 1 Day1,Visit 2 Day3, Visit 3 Day5

次要结局

  • Change in global assessment for overall improvement(Percentage of participants with adverse events)

研究者

发起方
Radhika Ayurveda Research and Development
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验